
Stoke Therapeutics Inc
NASDAQ:STOK

Stoke Therapeutics Inc?
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
Banking
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
Technology
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
US |
![]() |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
US |
![]() |
Visa Inc
NYSE:V
|
Technology
|
CN |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
US |
![]() |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
Beverages
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
Retail
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
We'll email you a reminder when the closing price reaches USD.
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
5.8
17.52
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
![]() |
Johnson & Johnson
NYSE:JNJ
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
US |
![]() |
Nike Inc
NYSE:NKE
|
US |
![]() |
Visa Inc
NYSE:V
|
US |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
![]() |
3M Co
NYSE:MMM
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.

What unique competitive advantages
does Stoke Therapeutics Inc hold over its rivals?
What risks and challenges
does Stoke Therapeutics Inc face in the near future?
Is it considered overvalued or undervalued
based on the latest financial data?
Provide an overview of the primary business activities
of Stoke Therapeutics Inc.
Provide an overview of the primary business activities
of Stoke Therapeutics Inc.
What unique competitive advantages
does Stoke Therapeutics Inc hold over its rivals?
What risks and challenges
does Stoke Therapeutics Inc face in the near future?
Has there been any significant insider trading activity
in Stoke Therapeutics Inc recently?
Is it considered overvalued or undervalued
based on the latest financial data?
Show all valuation multiples
for Stoke Therapeutics Inc.
Provide P/S
for Stoke Therapeutics Inc.
Provide P/E
for Stoke Therapeutics Inc.
Provide P/OCF
for Stoke Therapeutics Inc.
Provide P/FCFE
for Stoke Therapeutics Inc.
Provide P/B
for Stoke Therapeutics Inc.
Provide EV/S
for Stoke Therapeutics Inc.
Provide EV/GP
for Stoke Therapeutics Inc.
Provide EV/EBITDA
for Stoke Therapeutics Inc.
Provide EV/EBIT
for Stoke Therapeutics Inc.
Provide EV/OCF
for Stoke Therapeutics Inc.
Provide EV/FCFF
for Stoke Therapeutics Inc.
Provide EV/IC
for Stoke Therapeutics Inc.
Show me price targets
for Stoke Therapeutics Inc made by professional analysts.
What are the Revenue projections
for Stoke Therapeutics Inc?
How accurate were the past Revenue estimates
for Stoke Therapeutics Inc?
What are the Net Income projections
for Stoke Therapeutics Inc?
How accurate were the past Net Income estimates
for Stoke Therapeutics Inc?
What are the EPS projections
for Stoke Therapeutics Inc?
How accurate were the past EPS estimates
for Stoke Therapeutics Inc?
What are the EBIT projections
for Stoke Therapeutics Inc?
How accurate were the past EBIT estimates
for Stoke Therapeutics Inc?
Compare the revenue forecasts
for Stoke Therapeutics Inc with those of its competitors based on recent analyst estimates.
Compare the intrinsic valuations
of Stoke Therapeutics Inc and its key competitors using the latest financial data.
Compare historical revenue growth rates
of Stoke Therapeutics Inc against its competitors.
Analyze the profit margins
(gross, operating, and net) of Stoke Therapeutics Inc compared to its peers.
Compare the P/E ratios
of Stoke Therapeutics Inc against its peers.
Discuss the investment returns and shareholder value creation
comparing Stoke Therapeutics Inc with its peers.
Analyze the financial leverage
of Stoke Therapeutics Inc compared to its main competitors.
Show all profitability ratios
for Stoke Therapeutics Inc.
Provide ROE
for Stoke Therapeutics Inc.
Provide ROA
for Stoke Therapeutics Inc.
Provide ROIC
for Stoke Therapeutics Inc.
Provide ROCE
for Stoke Therapeutics Inc.
Provide Gross Margin
for Stoke Therapeutics Inc.
Provide Operating Margin
for Stoke Therapeutics Inc.
Provide Net Margin
for Stoke Therapeutics Inc.
Provide FCF Margin
for Stoke Therapeutics Inc.
Show all solvency ratios
for Stoke Therapeutics Inc.
Provide D/E Ratio
for Stoke Therapeutics Inc.
Provide D/A Ratio
for Stoke Therapeutics Inc.
Provide Interest Coverage Ratio
for Stoke Therapeutics Inc.
Provide Altman Z-Score Ratio
for Stoke Therapeutics Inc.
Provide Quick Ratio
for Stoke Therapeutics Inc.
Provide Current Ratio
for Stoke Therapeutics Inc.
Provide Cash Ratio
for Stoke Therapeutics Inc.
What is the historical Revenue growth
over the last 5 years for Stoke Therapeutics Inc?
What is the historical Net Income growth
over the last 5 years for Stoke Therapeutics Inc?
What is the current Free Cash Flow
of Stoke Therapeutics Inc?
Discuss the annual earnings per share (EPS)
trend over the past five years for Stoke Therapeutics Inc.
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
Market Cap | EV/EBITDA | ||||
---|---|---|---|---|---|
US |
![]() |
Stoke Therapeutics Inc
NASDAQ:STOK
|
455.3m USD | -1.9 | |
FR |
![]() |
Pharnext SCA
OTC:PNEXF
|
6T USD | -210 453.3 |
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
373.8B USD | 17.2 |
|
US |
![]() |
Amgen Inc
NASDAQ:AMGN
|
168.4B USD | 16.6 |
|
US |
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
138.9B USD | 11.3 |
|
US |
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
129.7B USD | 26.5 |
|
US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -536.9 |
|
AU |
![]() |
CSL Ltd
ASX:CSL
|
121.1B AUD | 17.2 |
|
US |
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
73.1B USD | 10.9 |
|
US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -61.4 |
|
NL |
![]() |
argenx SE
XBRU:ARGX
|
32.9B EUR | 317.6 |
|
EBITDA Growth | EV/EBITDA to Growth | |||||
---|---|---|---|---|---|---|
US |
![]() |
Stoke Therapeutics Inc
NASDAQ:STOK
|
Average EV/EBITDA:
59.6
|
N/A | N/A | |
FR |
![]() |
Pharnext SCA
OTC:PNEXF
|
Negative Multiple: -210 453.3 | N/A | N/A |
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
17.2
|
13%
|
1.3 |
|
US |
![]() |
Amgen Inc
NASDAQ:AMGN
|
16.6
|
14%
|
1.2 |
|
US |
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
11.3
|
6%
|
1.9 |
|
US |
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
26.5
|
16%
|
1.7 |
|
US |
E
|
Epizyme Inc
F:EPE
|
Negative Multiple: -536.9 | N/A | N/A |
|
AU |
![]() |
CSL Ltd
ASX:CSL
|
17.2
|
12%
|
1.4 |
|
US |
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
10.9
|
17%
|
0.6 |
|
US |
S
|
Seagen Inc
F:SGT
|
Negative Multiple: -61.4 | N/A | N/A |
|
NL |
![]() |
argenx SE
XBRU:ARGX
|
317.6
|
168%
|
1.9 |
|
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.